BioStem Technologies, Inc. (BSEM) Stock Price & Analysis
BioStem Technologies, Inc. (BSEM) closed at USD 2.04 on Thursday, October 15, 2026, down 3.32% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 2.11; the Oct 15, 2026 session ranged USD 1.88–2.3 on volume of 102,371 shares. Market capitalization is $38.09M, with a 52-week range of USD 1.88–8.4 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:22 UTC.
Also available as compact Markdown for AI agents: nexqual.com/BSEM.md
Key facts (BSEM)
- Analysts: Buy (mean 2.00 on a 1–5 scale) (1 analysts), mean target USD 7 (range 7–7).
- Total return with dividends: 1Y -56.7% vs S&P 500 +18.1%; 5Y +45.7% vs S&P 500 +85.1%.
- Next earnings: 2026-11-12, EPS estimate USD -0.43, revenue estimate $7.2M.
Analysts (BSEM)
Consensus Buy (mean 2.00 on a 1–5 scale), 1 analysts; mean target USD 7 (low 7, high 7).
Total return (dividends reinvested) (BSEM)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -56.7% | +45.7% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -56.8% | +7.8% |
| Volatility (annualized) | 115.1% | 110.7% |
| Max drawdown | -75.1% (Jan 2026→Oct 2026) | -91.0% (Nov 2024→Oct 2026) |
Key Statistics (as of October 16, 2026 at 05:22 UTC)
| Price | USD 2.04 |
|---|---|
| Change | ▼ 3.32% (down) |
| Previous Close | USD 2.11 |
| Open | USD 2.15 |
| Day Range | USD 1.88 – 2.3 |
| 52-Week Range | USD 1.88 – 8.4 |
| Volume | 102,371 shares |
| Market Cap | $38.09M |
| Exchange | NCM |
Technical Analysis (BSEM)
Nexqual's technical model rates BSEM "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:22 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 29.21 (oversold) |
| vs SMA50 | Below (USD 3.52) |
| MACD | -0.45 (negative) |
Analyst Ratings (BSEM)
Wall Street analysts rate BSEM "Buy" based on 1 analysts, with a mean price target of USD 7 (range USD 7–7), per Nexqual as of October 16, 2026 at 05:22 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 7 |
| High Target | USD 7 |
| Low Target | USD 7 |
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (BSEM)
| Next Earnings Date | 2026-11-12 |
|---|---|
| Revenue Estimate | $7.17M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.52 vs est -0.5 ▼ miss |
| 2026-03-31 | USD -0.52 vs est -0.28 ▼ miss |
| 2025-09-30 | USD 0.06 vs est 0 ▲ beat |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financials & Fundamentals (BSEM)
| Total Revenue | $34.59M |
|---|---|
| Revenue Growth (latest quarter, YoY) | -27.90% |
| Gross Margin | +79.94% |
| Operating Margin | -106.35% |
| Profit Margin | -81.80% |
| ROE | -74.74% |
| Debt / Equity | 0.04 |
| Current Ratio | 0.98 |
| Total Cash | $6.96M |
| Total Debt | $1.22M |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financial Health Score (BSEM)
Nexqual rates BioStem Technologies, Inc.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:22 UTC.
| Growth | Critical — Revenue -100% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Solid — $7M cash vs $1M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$6M (TTM) |
| Efficiency | Critical — ROE -75%, ROA -18.1% |
Ownership (BSEM)
| Insider Ownership | +31.35% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 18.67M |
| Float | 13.63M |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Leadership (BSEM)
BioStem Technologies, Inc. is led by Jason V. Matuszewski (age 39), CEO, President, Secretary & Chairman, per Nexqual as of October 16, 2026 at 05:22 UTC.
| CEO, President, Secretary & Chairman | Jason V. Matuszewski (age 39) |
|---|---|
| Chief Financial Officer | Brandon Poe (age 56) |
| COO & Director | Andrew Van Vurst CTBS (age 34) |
| Vice President of Corporate Finance & Strategy | Noah Agron |
| Vice President of Human Resources | Jeff Humke |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:22 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt